Home » Using NGS as CDx Will Require Paradigm Shift, Regulatory Changes, According to Experts at AACR

Using NGS as CDx Will Require Paradigm Shift, Regulatory Changes, According to Experts at AACR

Apr 16, 2014
|
Monica Heger
Premium

Next-generation sequencing holds promise for use in companion diagnostics, but will require a paradigm shift as well as changes to the regulatory landscape, according to a number of experts that presented at last week's American Association for Cancer Research meeting in San Diego.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

What's Popular?

In Clinical Sequencing

  1. Nanopore Sequencing Becomes More Portable to Enable Outbreak Surveillance in Field

    Premium

  2. Survey Finds QC Best Practices in Clinical Genomics Still Developing

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.